568 related articles for article (PubMed ID: 21613613)
1. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.
Duewell P; Kisser U; Heckelsmiller K; Hoves S; Stoitzner P; Koernig S; Morelli AB; Clausen BE; Dauer M; Eigler A; Anz D; Bourquin C; Maraskovsky E; Endres S; Schnurr M
J Immunol; 2011 Jul; 187(1):55-63. PubMed ID: 21613613
[TBL] [Abstract][Full Text] [Related]
2. ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway.
Wilson NS; Yang B; Morelli AB; Koernig S; Yang A; Loeser S; Airey D; Provan L; Hass P; Braley H; Couto S; Drane D; Boyle J; Belz GT; Ashkenazi A; Maraskovsky E
Immunol Cell Biol; 2012 May; 90(5):540-52. PubMed ID: 21894173
[TBL] [Abstract][Full Text] [Related]
3. ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II.
Schnurr M; Orban M; Robson NC; Shin A; Braley H; Airey D; Cebon J; Maraskovsky E; Endres S
J Immunol; 2009 Feb; 182(3):1253-9. PubMed ID: 19155470
[TBL] [Abstract][Full Text] [Related]
4. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.
Schnurr M; Chen Q; Shin A; Chen W; Toy T; Jenderek C; Green S; Miloradovic L; Drane D; Davis ID; Villadangos J; Shortman K; Maraskovsky E; Cebon J
Blood; 2005 Mar; 105(6):2465-72. PubMed ID: 15546948
[TBL] [Abstract][Full Text] [Related]
5. A Highly Active Form of XCL1/Lymphotactin Functions as an Effective Adjuvant to Recruit Cross-Presenting Dendritic Cells for Induction of Effector and Memory CD8
Matsuo K; Kitahata K; Kawabata F; Kamei M; Hara Y; Takamura S; Oiso N; Kawada A; Yoshie O; Nakayama T
Front Immunol; 2018; 9():2775. PubMed ID: 30542351
[TBL] [Abstract][Full Text] [Related]
6. The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8(+) T-cell responses: The immunological consequences of the biodistribution profile.
Schmidt ST; Khadke S; Korsholm KS; Perrie Y; Rades T; Andersen P; Foged C; Christensen D
J Control Release; 2016 Oct; 239():107-17. PubMed ID: 27574990
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic ISCOMATRIX™ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer.
Barr AM; Silva A; Prato S; Belz GT; Maraskovsky E; Baz Morelli A
Cancer Immunol Immunother; 2020 Oct; 69(10):1959-1972. PubMed ID: 32388678
[TBL] [Abstract][Full Text] [Related]
8. The combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo.
Silva A; Mount A; Krstevska K; Pejoski D; Hardy MP; Owczarek C; Scotney P; Maraskovsky E; Baz Morelli A
J Immunol; 2015 Mar; 194(5):2199-207. PubMed ID: 25646304
[TBL] [Abstract][Full Text] [Related]
9. Delivered antigen peptides to resident CD8α
Wang L; Wang Z; Qin Y; Liang W
Eur J Pharm Biopharm; 2020 Feb; 147():76-86. PubMed ID: 31887349
[TBL] [Abstract][Full Text] [Related]
10. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
12. Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery.
Robson NC; McAlpine T; Knights AJ; Schnurr M; Shin A; Chen W; Maraskovsky E; Cebon J
Blood; 2010 Jul; 116(2):218-25. PubMed ID: 20430956
[TBL] [Abstract][Full Text] [Related]
13. Langerhans cells prime IL-17-producing T cells and dampen genital cytotoxic responses following mucosal immunization.
Hervouet C; Luci C; Rol N; Rousseau D; Kissenpfennig A; Malissen B; Czerkinsky C; Anjuère F
J Immunol; 2010 May; 184(9):4842-51. PubMed ID: 20351191
[TBL] [Abstract][Full Text] [Related]
14. Langerin+ CD8alpha+ dendritic cells are critical for cross-priming and IL-12 production in response to systemic antigens.
Farrand KJ; Dickgreber N; Stoitzner P; Ronchese F; Petersen TR; Hermans IF
J Immunol; 2009 Dec; 183(12):7732-42. PubMed ID: 19923446
[TBL] [Abstract][Full Text] [Related]
15. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
16. A marked reduction in priming of cytotoxic CD8+ T cells mediated by stress-induced glucocorticoids involves multiple deficiencies in cross-presentation by dendritic cells.
Hunzeker JT; Elftman MD; Mellinger JC; Princiotta MF; Bonneau RH; Truckenmiller ME; Norbury CC
J Immunol; 2011 Jan; 186(1):183-94. PubMed ID: 21098225
[TBL] [Abstract][Full Text] [Related]
17. TLR7 triggering with polyuridylic acid promotes cross-presentation in CD8α+ conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell surface.
Crespo MI; Zacca ER; Núñez NG; Ranocchia RP; Maccioni M; Maletto BA; Pistoresi-Palencia MC; Morón G
J Immunol; 2013 Feb; 190(3):948-60. PubMed ID: 23284054
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell-mediated induction of mucosal cytotoxic responses following intravaginal immunization with the nontoxic B subunit of cholera toxin.
Luci C; Hervouet C; Rousseau D; Holmgren J; Czerkinsky C; Anjuère F
J Immunol; 2006 Mar; 176(5):2749-57. PubMed ID: 16493030
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration.
Schmidt ST; Olsen CL; Franzyk H; Wørzner K; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
Eur J Pharm Biopharm; 2019 Jul; 140():29-39. PubMed ID: 31055066
[TBL] [Abstract][Full Text] [Related]
20. Transcutaneous immunization with a highly active form of XCL1 as a vaccine adjuvant using a hydrophilic gel patch elicits long-term CD8
Kamei M; Matsuo K; Imanishi H; Hara Y; Quen YS; Kamiyama F; Oiso N; Kawada A; Okada N; Nakayama T
J Pharmacol Sci; 2020 Jul; 143(3):182-187. PubMed ID: 32386904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
